Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | UBE2N | P61088 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24846114 | 0.89 | KMT2A (0.48) | GLSKDM4EKMT2ATSHRCYP1A2 | |
| SCHEMBL24846119 | 0.85 | KMT2A (0.39) | GLSKDM4EKMT2ARXFP1TSHR | |
| SCHEMBL24846054 | 0.84 | KMT2A (0.43) | KDM4EKMT2ARXFP1TSHRALDH1A1 | |
| SCHEMBL24846095 | 0.82 | DGAT1 (0.42) | GLSKDM4EKMT2ATSHRALDH1A1 | |
| SCHEMBL24846672 | 0.82 | SMN1; SMN2 (0.42) | KDM4EKMT2ATSHRALDH1A1CYP1A2 | |
| SCHEMBL24846717 | 0.82 | CFTR (0.45) | GLSKMT2ARXFP1ALDH1A1POLB | |
| SCHEMBL29837159 | 0.79 | NPC1 (0.47) | GLSKDM4EKMT2ATSHRALDH1A1 | |
| SCHEMBL28952720 | 0.79 | NPC1 (0.47) | GLSKDM4EKMT2ATSHRALDH1A1 | |
| SCHEMBL24846098 | 0.79 | NPC1 (0.47) | GLSKDM4EKMT2ATSHRALDH1A1 | |
| SCHEMBL24846064 | 0.79 | KMT2A (0.47) | GLSKMT2ATSHRCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002336-A1 | MrgprX2 Antagonists and Uses Thereof | DERMIRA, INC. | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002336-A1 | MrgprX2 Antagonists and Uses Thereof | MRGPRX2, MRGPRX1, MRGPRX4 | GLS 1237/4885KDM4E 3619/4885KMT2A 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.